<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00929110</url>
  </required_header>
  <id_info>
    <org_study_id>CNVA237A2303</org_study_id>
    <secondary_id>2008-008394-63</secondary_id>
    <nct_id>NCT00929110</nct_id>
  </id_info>
  <brief_title>1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>GLOW2</acronym>
  <official_title>A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study was designed to investigate the 1 year efficacy and safety of the 50 µg once daily
      (od) dose of glycopyrronium bromide (NVA237) in patients with moderate to severe chronic
      obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 15 minutes and 23 hours 45 minutes post-dose. The analysis included baseline FEV1 measurement, baseline inhaled corticosteroid use (Yes/No), FEV1 prior to inhalation of short-acting β2 agonist (SABA), and FEV1 45 min post-inhalation of SABA as covariates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transition Dyspnea Index (TDI) at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>The TDI measured changes in dyspnea from baseline during treatment and included 3 domains: Functional impairment (activities of daily living), magnitude of task (intensity of activity), and magnitude of effort (difficulty breathing). Each domain was rated from -3 to 3 (major deterioration-major improvement). The total score ranged from -9 to 9; minus scores indicate deterioration. The analysis included the same covariates as the primary Outcome Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (QoL) Assessed With the St. George Respiratory Questionnaire (SGRQ) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The SGRQ contained 51 patient-rated items divided into three components: Symptoms (respiratory symptoms, their frequency, and severity), Activity (activities that cause or are limited by breathlessness), and Impacts (social functioning and psychological disturbances resulting from airway disease). A total score for the 3 components was calculated and ranged from 0 to 100. Higher values indicate greater impairment of QoL. The analysis included the same covariates as the primary Outcome Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the Study (Baseline to Week 52)</measure>
    <time_frame>Baseline to Week 52 (patients with no moderate or severe exacerbations who completed the study were censored at the final visit date, which may have exceeded 52 weeks)</time_frame>
    <description>Time to first moderate or severe COPD exacerbation was calculated as the number of days from baseline to the day on which the patient experienced the first moderate or severe COPD exacerbation. A COPD exacerbation was considered to be moderate if treatment with systemic corticosteroids and/or antibiotic was required. A COPD exacerbation was considered to be severe if treatment for moderate severity and hospitalization was required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Taken During the Study (Baseline to Week 52)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>The number of puffs of rescue medication taken in the previous 12 hours was recorded in the Patient Diary in the morning and evening. The mean daily number of puffs of rescue medication taken was calculated by dividing the number of puffs of rescue medication per day over the 52 weeks of the study by the number of days with non-missing rescue medication data. Rescue medication data recorded during the 14 day run-in period was used to calculate the baseline. The analysis included the same covariates as the primary Outcome Measure. A positive change score indicates more puffs taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1, Week 26, and Week 52</measure>
    <time_frame>Day 1, Week 26, and Week 52</time_frame>
    <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 15 minutes and 23 hours 45 minutes post-dose. The analysis included the same covariates as the primary Outcome Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Vital Capacity (FVC) at Day 1, Week 12, Week 26, and Week 52</measure>
    <time_frame>Day 1, Week 12, Week 26, and Week 52</time_frame>
    <description>Trough FVC is defined as the average of the post-dose 23 h 15 min and the 23 h 45 min FVC values. Just prior to FVC measurement, patients performed normal tidal breathing. The patient was given a few breaths warning before being told &quot;At the end of the next normal breath out, take a deep breath all the way in&quot;; they were then verbally encouraged to make a maximal effort before relaxing. The analysis included the same covariates as the primary Outcome Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) 5, 15, and 30 Minutes; 1, 2, 3, 4, 6, 8, 10, and 12 Hours; 23 Hours 15 Minutes; and 23 Hours 45 Minutes Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</measure>
    <time_frame>5, 15, and 30 minutes; 1, 2, 3, 4, 6, 8, 10, and 12 hours; 23 hours 15 minutes; and 23 hours 45 minutes post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</time_frame>
    <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) 5, 15, and 30 Minutes; 1, 2, 3, 4, 6, 8, 10, and 12 Hours; 23 Hours 15 Minutes; and 23 Hours 45 Minutes Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</measure>
    <time_frame>5, 15, and 30 minutes; 1, 2, 3, 4, 6, 8, 10, and 12 hours; 23 hours 15 minutes; and 23 hours 45 minutes post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</time_frame>
    <description>Just prior to FVC measurement, patients performed normal tidal breathing. The patient was given a few breaths warning before being told &quot;At the end of the next normal breath out, take a deep breath all the way in&quot;; they were then verbally encouraged to make a maximal effort before relaxing. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) 5, 15, and 30 Minutes; and 1, 2, 3, and 4 Hours Post Dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</measure>
    <time_frame>5, 15, and 30 minutes; and 1, 2, 3, 4 hours post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</time_frame>
    <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) 5, 15, and 30 Minutes; and 1, 2, 3, and 4 Hours Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</measure>
    <time_frame>5, 15, and 30 minutes; and 1, 2, 3, 4 hours post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</time_frame>
    <description>Just prior to FVC measurement, patients performed normal tidal breathing. The patient was given a few breaths warning before being told &quot;At the end of the next normal breath out, take a deep breath all the way in&quot;; they were then verbally encouraged to make a maximal effort before relaxing. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose at Day 1 and Weeks 12, 26, and 52</measure>
    <time_frame>From 5 minutes to 4 hours post-dose at Day 1 and Weeks 12, 26, and 52</time_frame>
    <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, 3, and 4 hours post-dose. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included the same covariates as the primary Outcome Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 12 Hours Post-dose at Day 1 and Weeks 12 and 52</measure>
    <time_frame>From 5 minutes to 12 hours post-dose at Day 1 and Weeks 12 and 52</time_frame>
    <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, 3, 4, 6, 8 10, and 12 hours post-dose. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included the same covariates as the primary Outcome Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 23 Hours 45 Minutes and From 12 Hours to 23 Hours 45 Minutes Post-dose at Weeks 12 and 52</measure>
    <time_frame>From 5 minutes to 23 hours 45 minutes post-dose at Weeks 12 and 52</time_frame>
    <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; 1, 2, 3, 4, 6, 8, 10, and 12 hours; 23 hours 15 minutes; and 23 hours 45 minutes post-dose. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included the same covariates as the primary Outcome Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Moderate or Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Per Year During the Study (Baseline to Week 52)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>The number of moderate or severe exacerbations of COPD per year during the study was calculated by dividing the total number of exacerbations during the study by the total number of years of treatment. A COPD exacerbation was considered to be moderate if treatment with systemic corticosteroids and/or antibiotic was required. A COPD exacerbation was considered to be severe if treatment for moderate severity and hospitalization was required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Experienced a Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the Study (Baseline to Week 52)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>A COPD exacerbation was considered to be moderate if treatment with systemic corticosteroids and/or antibiotic was required. A COPD exacerbation was considered to be severe if treatment for moderate severity and hospitalization was required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Nights With &quot;no Nighttime Awakenings&quot; During the Study (Baseline to Week 52)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>A night with &quot;no nighttime awakenings&quot; was defined as any night where the patient did not wake up due to 1 or more of 6 symptoms (respiratory symptoms, cough, wheeze, amount of sputum, color of sputum, and breathlessness). Symptoms occurring during the previous 12 hours were recorded each morning and evening by the patient in an electronic diary. The percentage of nights with 'no nighttime awakenings' was calculated as the total number of nights with &quot;no nighttime awakenings&quot; over the 52 week treatment period divided by the total number of nights where diary recordings were made.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With &quot;no Daytime Symptoms&quot; During the Study (Baseline to Week 52)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>A day with &quot;no daytime symptoms&quot; was defined as any day where the patient recorded no cough, no wheeze, no production of sputum, no feeling of breathlessness (other than when running), and no puffs of rescue medication during the previous 12 hours in evening entry in the electronic patient diary. The percentage of days with &quot;no daytime symptoms&quot; was calculated as the total number of days with &quot;no daytime symptoms&quot; over the 52 week treatment period divided by the total number of days where diary recordings were made.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of &quot;Days Able to Perform Usual Daily Activities&quot; During the Study (Baseline to Week 52)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>A &quot;day able to perform usual daily activities&quot; was defined as any day where the patient recorded in their electronic diary in the evening that they were not prevented from performing their usual daily activities due to respiratory symptoms during the previous 12 hours. The percentage of &quot;days able to perform usual daily activities&quot; was calculated as the total number of &quot;days able to perform usual daily activities&quot; over the 52 week treatment period divided by the total number of days where diary recordings were made.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Daily Total Symptom Score During the Study (Baseline to Week 52)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>The daily total symptom score was defined as the sum of the morning and evening patient self-reported diary assessments of 6 symptoms (respiratory symptoms/impact on daily activities, cough, wheeze, amount of sputum, color of sputum, and breathlessness). Means for baseline (14 day maximum run-in period) and the 52 week treatment period were calculated. Mean scores ranged from 0-18, with a higher score indicating worse symptoms. A negative change score indicated improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1066</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Glycopyrronium bromide 50 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to glycopyrronium bromide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium 18 μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium bromide</intervention_name>
    <description>Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.</description>
    <arm_group_label>Glycopyrronium bromide 50 μg</arm_group_label>
    <other_name>NVA237</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to glycopyrronium bromide</intervention_name>
    <description>Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.</description>
    <arm_group_label>Placebo to glycopyrronium bromide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.</description>
    <arm_group_label>Tiotropium 18 μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adults aged ≥ 40 years, who have signed an Informed Consent Form prior
             to initiation of any study-related procedure.

          2. Patients with moderate to severe stable chronic obstructive pulmonary disease (COPD,
             Stage II or Stage III) according to the Global Initiative for Chronic Obstructive Lung
             Disease (GOLD) Guidelines 2008.

          3. Current or ex-smokers who have a smoking history of at least 10 pack years.

          4. Patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 30%
             and &lt; 80% of the predicted normal, and post-bronchodilator FEV1/forced vital capacity
             (FVC) &lt; 0.7 at Visit 2 (Day -14).

          5. Patients, according to daily electronic diary data between Visit 2 (Day -14) and Visit
             3 (Day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to
             Visit 3 (Day 1).

        Exclusion Criteria:

          1. Pregnant women or nursing mothers (pregnancy confirmed by positive urine pregnancy
             test).

          2. Women of child-bearing potential, unless using an approved method of medical or
             surgical contraception.

          3. Patients requiring long term oxygen therapy (&gt; 15 h a day) on a daily basis for
             chronic hypoxemia, or who have been hospitalized for an exacerbation of their airways
             disease in the 6 weeks prior to Visit 1 (Day -21) or between Visit 1 (Day -21) and
             Visit 3 (Day 1).

          4. Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1
             (Day -21).

          5. Patients who, in the judgment of the investigator or the responsible Novartis
             personnel, have a clinically relevant laboratory abnormality or a clinically
             significant condition.

          6. Patients with any history of asthma indicated by (but not limited to) a blood
             eosinophil count &gt; 600/mm^3 (at Visit 1, Day -21) and onset of symptoms prior to age
             40 years.

          7. Patients with a history of long QT syndrome or whose QTc measured at Visit 1 (Day -21)
             (Fridericia method) is prolonged (&gt; 450 ms for males or &gt; 470 ms for females.

        Other protocol-defined inclusion/exclusion criteria may apply to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712-151</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33316-192</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <zip>30096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Coeur D'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150-3054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503-4658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Shawnee</city>
        <state>Kansas</state>
        <zip>66216-1800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Center</name>
      <address>
        <city>Crescent Springs</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017-542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <zip>70584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Boys Town</city>
        <state>Maine</state>
        <zip>68010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taunton</city>
        <state>Massachusetts</state>
        <zip>02780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504-8741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>92713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Downingtown</city>
        <state>Pennsylvania</state>
        <zip>19335-2620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130-6113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604-1584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405-4266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Plata - Bueno Aire</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parana Entre Rios</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Brampton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kelowna</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Langley</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Niagara Falls</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ste-Foy</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Talcahuano</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vina del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rennes Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Landsberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyonsyos</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siokok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyeonggi-go</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Surco</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bystra</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrow Wielkopolski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Piekary Slaskic</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tarnow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <results_first_submitted>June 22, 2012</results_first_submitted>
  <results_first_submitted_qc>June 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 27, 2012</results_first_posted>
  <disposition_first_submitted>October 25, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>October 25, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 31, 2011</disposition_first_posted>
  <last_update_submitted>August 9, 2012</last_update_submitted>
  <last_update_submitted_qc>August 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>NVA237</keyword>
  <keyword>glycopyrronium bromide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1993 patients were screened from 180 participating sites, of whom 1066 were randomized to 1 of the 3 treatment groups in a 2:1:1 ratio glycopyrronium bromide:placebo:tiotropium.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Glycopyrronium Bromide 50 μg</title>
          <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="P2">
          <title>Placebo to Glycopyrronium Bromide</title>
          <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="P3">
          <title>Tiotropium 18 μg</title>
          <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="529"/>
                <participants group_id="P2" count="269"/>
                <participants group_id="P3" count="268"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="411"/>
                <participants group_id="P2" count="193"/>
                <participants group_id="P3" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient inability to use the device</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glycopyrronium Bromide 50 μg</title>
          <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="B2">
          <title>Placebo to Glycopyrronium Bromide</title>
          <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="B3">
          <title>Tiotropium 18 μg</title>
          <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="525"/>
            <count group_id="B2" value="268"/>
            <count group_id="B3" value="267"/>
            <count group_id="B4" value="1060"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Demographic data are based on the safety population which was defined as all patients who received at least 1 dose of study medication whether they were randomized or not. The number of patients in the safety population was less than the number of randomized patients, ie, some randomized patients did not receive study medication (4 in the glycopyrronium bromide group, 1 in the placebo group, and 1 in the tiotropium group).</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="9.05"/>
                    <measurement group_id="B2" value="63.6" spread="9.14"/>
                    <measurement group_id="B3" value="63.9" spread="8.25"/>
                    <measurement group_id="B4" value="63.6" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Demographic data are based on the safety population which was defined as all patients who received at least 1 dose of study medication whether they were randomized or not. The number of patients in the safety population was less than the number of randomized patients, ie, some randomized patients did not receive study medication (4 in the glycopyrronium bromide group, 1 in the placebo group, and 1 in the tiotropium group).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="339"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="168"/>
                    <measurement group_id="B4" value="680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12</title>
        <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 15 minutes and 23 hours 45 minutes post-dose. The analysis included baseline FEV1 measurement, baseline inhaled corticosteroid use (Yes/No), FEV1 prior to inhalation of short-acting β2 agonist (SABA), and FEV1 45 min post-inhalation of SABA as covariates.</description>
        <time_frame>Week 12</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12</title>
          <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 15 minutes and 23 hours 45 minutes post-dose. The analysis included baseline FEV1 measurement, baseline inhaled corticosteroid use (Yes/No), FEV1 prior to inhalation of short-acting β2 agonist (SABA), and FEV1 45 min post-inhalation of SABA as covariates.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="513"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.469" spread="0.0141"/>
                    <measurement group_id="O2" value="1.372" spread="0.0173"/>
                    <measurement group_id="O3" value="1.455" spread="0.0170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transition Dyspnea Index (TDI) at Week 26</title>
        <description>The TDI measured changes in dyspnea from baseline during treatment and included 3 domains: Functional impairment (activities of daily living), magnitude of task (intensity of activity), and magnitude of effort (difficulty breathing). Each domain was rated from -3 to 3 (major deterioration-major improvement). The total score ranged from -9 to 9; minus scores indicate deterioration. The analysis included the same covariates as the primary Outcome Measure.</description>
        <time_frame>Week 26</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Transition Dyspnea Index (TDI) at Week 26</title>
          <description>The TDI measured changes in dyspnea from baseline during treatment and included 3 domains: Functional impairment (activities of daily living), magnitude of task (intensity of activity), and magnitude of effort (difficulty breathing). Each domain was rated from -3 to 3 (major deterioration-major improvement). The total score ranged from -9 to 9; minus scores indicate deterioration. The analysis included the same covariates as the primary Outcome Measure.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="0.240"/>
                    <measurement group_id="O2" value="1.32" spread="0.289"/>
                    <measurement group_id="O3" value="2.26" spread="0.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (QoL) Assessed With the St. George Respiratory Questionnaire (SGRQ) at Week 52</title>
        <description>The SGRQ contained 51 patient-rated items divided into three components: Symptoms (respiratory symptoms, their frequency, and severity), Activity (activities that cause or are limited by breathlessness), and Impacts (social functioning and psychological disturbances resulting from airway disease). A total score for the 3 components was calculated and ranged from 0 to 100. Higher values indicate greater impairment of QoL. The analysis included the same covariates as the primary Outcome Measure.</description>
        <time_frame>Week 52</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (QoL) Assessed With the St. George Respiratory Questionnaire (SGRQ) at Week 52</title>
          <description>The SGRQ contained 51 patient-rated items divided into three components: Symptoms (respiratory symptoms, their frequency, and severity), Activity (activities that cause or are limited by breathlessness), and Impacts (social functioning and psychological disturbances resulting from airway disease). A total score for the 3 components was calculated and ranged from 0 to 100. Higher values indicate greater impairment of QoL. The analysis included the same covariates as the primary Outcome Measure.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="499"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.85" spread="0.854"/>
                    <measurement group_id="O2" value="44.16" spread="1.040"/>
                    <measurement group_id="O3" value="41.32" spread="1.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the Study (Baseline to Week 52)</title>
        <description>Time to first moderate or severe COPD exacerbation was calculated as the number of days from baseline to the day on which the patient experienced the first moderate or severe COPD exacerbation. A COPD exacerbation was considered to be moderate if treatment with systemic corticosteroids and/or antibiotic was required. A COPD exacerbation was considered to be severe if treatment for moderate severity and hospitalization was required.</description>
        <time_frame>Baseline to Week 52 (patients with no moderate or severe exacerbations who completed the study were censored at the final visit date, which may have exceeded 52 weeks)</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the Study (Baseline to Week 52)</title>
          <description>Time to first moderate or severe COPD exacerbation was calculated as the number of days from baseline to the day on which the patient experienced the first moderate or severe COPD exacerbation. A COPD exacerbation was considered to be moderate if treatment with systemic corticosteroids and/or antibiotic was required. A COPD exacerbation was considered to be severe if treatment for moderate severity and hospitalization was required.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="268"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363.0" lower_limit="1" upper_limit="402"/>
                    <measurement group_id="O2" value="231.0" lower_limit="1" upper_limit="380"/>
                    <measurement group_id="O3" value="364.0" lower_limit="1" upper_limit="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Taken During the Study (Baseline to Week 52)</title>
        <description>The number of puffs of rescue medication taken in the previous 12 hours was recorded in the Patient Diary in the morning and evening. The mean daily number of puffs of rescue medication taken was calculated by dividing the number of puffs of rescue medication per day over the 52 weeks of the study by the number of days with non-missing rescue medication data. Rescue medication data recorded during the 14 day run-in period was used to calculate the baseline. The analysis included the same covariates as the primary Outcome Measure. A positive change score indicates more puffs taken.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Taken During the Study (Baseline to Week 52)</title>
          <description>The number of puffs of rescue medication taken in the previous 12 hours was recorded in the Patient Diary in the morning and evening. The mean daily number of puffs of rescue medication taken was calculated by dividing the number of puffs of rescue medication per day over the 52 weeks of the study by the number of days with non-missing rescue medication data. Rescue medication data recorded during the 14 day run-in period was used to calculate the baseline. The analysis included the same covariates as the primary Outcome Measure. A positive change score indicates more puffs taken.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="0.151"/>
                    <measurement group_id="O2" value="-1.20" spread="0.184"/>
                    <measurement group_id="O3" value="-1.83" spread="0.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1, Week 26, and Week 52</title>
        <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 15 minutes and 23 hours 45 minutes post-dose. The analysis included the same covariates as the primary Outcome Measure.</description>
        <time_frame>Day 1, Week 26, and Week 52</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1, Week 26, and Week 52</title>
          <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 15 minutes and 23 hours 45 minutes post-dose. The analysis included the same covariates as the primary Outcome Measure.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.478" spread="0.0088"/>
                    <measurement group_id="O2" value="1.388" spread="0.0109"/>
                    <measurement group_id="O3" value="1.471" spread="0.0109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=451, 219, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.458" spread="0.0161"/>
                    <measurement group_id="O2" value="1.324" spread="0.0196"/>
                    <measurement group_id="O3" value="1.408" spread="0.0191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=416, 196, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.412" spread="0.0157"/>
                    <measurement group_id="O2" value="1.303" spread="0.0198"/>
                    <measurement group_id="O3" value="1.392" spread="0.0191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Vital Capacity (FVC) at Day 1, Week 12, Week 26, and Week 52</title>
        <description>Trough FVC is defined as the average of the post-dose 23 h 15 min and the 23 h 45 min FVC values. Just prior to FVC measurement, patients performed normal tidal breathing. The patient was given a few breaths warning before being told “At the end of the next normal breath out, take a deep breath all the way in”; they were then verbally encouraged to make a maximal effort before relaxing. The analysis included the same covariates as the primary Outcome Measure.</description>
        <time_frame>Day 1, Week 12, Week 26, and Week 52</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Vital Capacity (FVC) at Day 1, Week 12, Week 26, and Week 52</title>
          <description>Trough FVC is defined as the average of the post-dose 23 h 15 min and the 23 h 45 min FVC values. Just prior to FVC measurement, patients performed normal tidal breathing. The patient was given a few breaths warning before being told “At the end of the next normal breath out, take a deep breath all the way in”; they were then verbally encouraged to make a maximal effort before relaxing. The analysis included the same covariates as the primary Outcome Measure.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.936" spread="0.0165"/>
                    <measurement group_id="O2" value="2.757" spread="0.0205"/>
                    <measurement group_id="O3" value="2.930" spread="0.0206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=442, 204, 217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.985" spread="0.0265"/>
                    <measurement group_id="O2" value="2.802" spread="0.0329"/>
                    <measurement group_id="O3" value="2.970" spread="0.0323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=418, 196, 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.962" spread="0.0299"/>
                    <measurement group_id="O2" value="2.758" spread="0.0361"/>
                    <measurement group_id="O3" value="2.892" spread="0.0355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=395, 186, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.866" spread="0.0335"/>
                    <measurement group_id="O2" value="2.687" spread="0.0399"/>
                    <measurement group_id="O3" value="2.866" spread="0.0383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) 5, 15, and 30 Minutes; 1, 2, 3, 4, 6, 8, 10, and 12 Hours; 23 Hours 15 Minutes; and 23 Hours 45 Minutes Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</title>
        <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.</description>
        <time_frame>5, 15, and 30 minutes; 1, 2, 3, 4, 6, 8, 10, and 12 hours; 23 hours 15 minutes; and 23 hours 45 minutes post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</time_frame>
        <population>Full Analysis Set (FAS), serial spirometry subgroup: A subgroup of approximately one third of all randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) 5, 15, and 30 Minutes; 1, 2, 3, 4, 6, 8, 10, and 12 Hours; 23 Hours 15 Minutes; and 23 Hours 45 Minutes Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</title>
          <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.</description>
          <population>Full Analysis Set (FAS), serial spirometry subgroup: A subgroup of approximately one third of all randomized patients who received at least 1 dose of study medication.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, minute 5 (n=135, 74, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.494" spread="0.0135"/>
                    <measurement group_id="O2" value="1.416" spread="0.0166"/>
                    <measurement group_id="O3" value="1.447" spread="0.0164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, minute 15 (n=139, 75, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.548" spread="0.0152"/>
                    <measurement group_id="O2" value="1.428" spread="0.0185"/>
                    <measurement group_id="O3" value="1.485" spread="0.0185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, minute 30 (n=143, 77, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.561" spread="0.0180"/>
                    <measurement group_id="O2" value="1.409" spread="0.0218"/>
                    <measurement group_id="O3" value="1.483" spread="0.0219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 1 (n=144, 76, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.583" spread="0.0172"/>
                    <measurement group_id="O2" value="1.404" spread="0.0213"/>
                    <measurement group_id="O3" value="1.514" spread="0.0212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 2 (n=144, 75, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.639" spread="0.0202"/>
                    <measurement group_id="O2" value="1.445" spread="0.0248"/>
                    <measurement group_id="O3" value="1.569" spread="0.0247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 3 (n=143, 74, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.629" spread="0.0199"/>
                    <measurement group_id="O2" value="1.435" spread="0.0249"/>
                    <measurement group_id="O3" value="1.587" spread="0.0248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 4 (n=144, 70, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.599" spread="0.0221"/>
                    <measurement group_id="O2" value="1.415" spread="0.0281"/>
                    <measurement group_id="O3" value="1.560" spread="0.0275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 6 (n=142, 71, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.578" spread="0.0204"/>
                    <measurement group_id="O2" value="1.426" spread="0.0255"/>
                    <measurement group_id="O3" value="1.575" spread="0.0252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 8 (n=137, 70, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.544" spread="0.0226"/>
                    <measurement group_id="O2" value="1.431" spread="0.0284"/>
                    <measurement group_id="O3" value="1.545" spread="0.0278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, hour 10 (n=134, 72, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.546" spread="0.0235"/>
                    <measurement group_id="O2" value="1.415" spread="0.0290"/>
                    <measurement group_id="O3" value="1.537" spread="0.0286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 12 (n=130, 69, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.522" spread="0.0254"/>
                    <measurement group_id="O2" value="1.369" spread="0.0307"/>
                    <measurement group_id="O3" value="1.480" spread="0.0306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 23, minute 15 (n=129, 71, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.471" spread="0.0214"/>
                    <measurement group_id="O2" value="1.396" spread="0.0259"/>
                    <measurement group_id="O3" value="1.481" spread="0.0255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 23, minute 45 (n=128, 74, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.518" spread="0.0210"/>
                    <measurement group_id="O2" value="1.446" spread="0.0252"/>
                    <measurement group_id="O3" value="1.499" spread="0.0249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, minute 5 (n=135, 65, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.494" spread="0.0246"/>
                    <measurement group_id="O2" value="1.421" spread="0.0315"/>
                    <measurement group_id="O3" value="1.490" spread="0.0299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, minute 15 (n=133, 70, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.530" spread="0.0246"/>
                    <measurement group_id="O2" value="1.411" spread="0.0307"/>
                    <measurement group_id="O3" value="1.537" spread="0.0303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, minute 30 (n= 139, 70, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.551" spread="0.0236"/>
                    <measurement group_id="O2" value="1.417" spread="0.0297"/>
                    <measurement group_id="O3" value="1.516" spread="0.0289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, hour 1 (n=140, 68, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.575" spread="0.0242"/>
                    <measurement group_id="O2" value="1.409" spread="0.0305"/>
                    <measurement group_id="O3" value="1.540" spread="0.0296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, minute 5 (n=134, 66, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.550" spread="0.0247"/>
                    <measurement group_id="O2" value="1.448" spread="0.0319"/>
                    <measurement group_id="O3" value="1.525" spread="0.0305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, minute 15 (n=136, 67, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.575" spread="0.0239"/>
                    <measurement group_id="O2" value="1.452" spread="0.0305"/>
                    <measurement group_id="O3" value="1.543" spread="0.0295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, minute 30 (n=135, 67, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.630" spread="0.0260"/>
                    <measurement group_id="O2" value="1.481" spread="0.0327"/>
                    <measurement group_id="O3" value="1.584" spread="0.0317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, minute 5 (n=128, 66, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.562" spread="0.0268"/>
                    <measurement group_id="O2" value="1.417" spread="0.0341"/>
                    <measurement group_id="O3" value="1.520" spread="0.0326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, minute 15 (n=130, 66, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.583" spread="0.0267"/>
                    <measurement group_id="O2" value="1.441" spread="0.0340"/>
                    <measurement group_id="O3" value="1.534" spread="0.0326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, minute 30 (n=130, 67, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.603" spread="0.0265"/>
                    <measurement group_id="O2" value="1.427" spread="0.0335"/>
                    <measurement group_id="O3" value="1.549" spread="0.0323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, minute 5 (n=130, 69, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.497" spread="0.0254"/>
                    <measurement group_id="O2" value="1.385" spread="0.0319"/>
                    <measurement group_id="O3" value="1.474" spread="0.0315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, minute 15 (n=129, 67, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.523" spread="0.0251"/>
                    <measurement group_id="O2" value="1.373" spread="0.0317"/>
                    <measurement group_id="O3" value="1.481" spread="0.0315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, minute 30 (n=133, 69, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.517" spread="0.0275"/>
                    <measurement group_id="O2" value="1.362" spread="0.0336"/>
                    <measurement group_id="O3" value="1.488" spread="0.0335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 1 (n=132, 67, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.557" spread="0.0273"/>
                    <measurement group_id="O2" value="1.369" spread="0.0341"/>
                    <measurement group_id="O3" value="1.519" spread="0.0333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 2 (n=129, 65, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.596" spread="0.0290"/>
                    <measurement group_id="O2" value="1.434" spread="0.0365"/>
                    <measurement group_id="O3" value="1.565" spread="0.0353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 3 (n=126, 64, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.600" spread="0.0291"/>
                    <measurement group_id="O2" value="1.443" spread="0.0375"/>
                    <measurement group_id="O3" value="1.566" spread="0.0353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 4 (n=124, 64, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.584" spread="0.0319"/>
                    <measurement group_id="O2" value="1.442" spread="0.0407"/>
                    <measurement group_id="O3" value="1.535" spread="0.0383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 6 (n=123, 63, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.558" spread="0.0321"/>
                    <measurement group_id="O2" value="1.443" spread="0.0407"/>
                    <measurement group_id="O3" value="1.520" spread="0.0381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 8 (n=121, 64, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.535" spread="0.0310"/>
                    <measurement group_id="O2" value="1.408" spread="0.0385"/>
                    <measurement group_id="O3" value="1.479" spread="0.0374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 10 (n=124, 61, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.541" spread="0.0296"/>
                    <measurement group_id="O2" value="1.435" spread="0.0392"/>
                    <measurement group_id="O3" value="1.532" spread="0.0365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 12 (n=122, 58, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.522" spread="0.0313"/>
                    <measurement group_id="O2" value="1.422" spread="0.0417"/>
                    <measurement group_id="O3" value="1.487" spread="0.0382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 16 (n=109, 56, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.431" spread="0.0320"/>
                    <measurement group_id="O2" value="1.360" spread="0.0425"/>
                    <measurement group_id="O3" value="1.378" spread="0.0404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 22 (n=117, 60, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.420" spread="0.0268"/>
                    <measurement group_id="O2" value="1.349" spread="0.0350"/>
                    <measurement group_id="O3" value="1.371" spread="0.0333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 23, minute 15 (n=126, 66, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.518" spread="0.0269"/>
                    <measurement group_id="O2" value="1.456" spread="0.0345"/>
                    <measurement group_id="O3" value="1.520" spread="0.0335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 23, minute 45 (n=124, 65, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.513" spread="0.0294"/>
                    <measurement group_id="O2" value="1.470" spread="0.0377"/>
                    <measurement group_id="O3" value="1.488" spread="0.0374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, minute 5 (n=123, 65, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.538" spread="0.0296"/>
                    <measurement group_id="O2" value="1.430" spread="0.0362"/>
                    <measurement group_id="O3" value="1.515" spread="0.0359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, minute 15 (n=124, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.557" spread="0.0309"/>
                    <measurement group_id="O2" value="1.422" spread="0.0380"/>
                    <measurement group_id="O3" value="1.530" spread="0.0377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, minute 30 (n=125, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.570" spread="0.0303"/>
                    <measurement group_id="O2" value="1.409" spread="0.0370"/>
                    <measurement group_id="O3" value="1.535" spread="0.0368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20, minute 5 (n=125, 66, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.518" spread="0.0281"/>
                    <measurement group_id="O2" value="1.393" spread="0.0348"/>
                    <measurement group_id="O3" value="1.453" spread="0.0351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20, minute 15 (n=124, 65, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.535" spread="0.0285"/>
                    <measurement group_id="O2" value="1.380" spread="0.0354"/>
                    <measurement group_id="O3" value="1.479" spread="0.0356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20, minute 30 (n=125, 65, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.576" spread="0.0277"/>
                    <measurement group_id="O2" value="1.391" spread="0.0349"/>
                    <measurement group_id="O3" value="1.502" spread="0.0350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, minute 5 (n=123, 62, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.483" spread="0.0278"/>
                    <measurement group_id="O2" value="1.361" spread="0.0368"/>
                    <measurement group_id="O3" value="1.415" spread="0.0352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, minute 15 (n=121, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.521" spread="0.0280"/>
                    <measurement group_id="O2" value="1.377" spread="0.0373"/>
                    <measurement group_id="O3" value="1.464" spread="0.0358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, minute 30 (n=125, 64, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.529" spread="0.0285"/>
                    <measurement group_id="O2" value="1.353" spread="0.0372"/>
                    <measurement group_id="O3" value="1.439" spread="0.0359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 1 (n=127, 64, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.546" spread="0.0275"/>
                    <measurement group_id="O2" value="1.364" spread="0.0359"/>
                    <measurement group_id="O3" value="1.462" spread="0.0349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 2 (n=124, 64, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.590" spread="0.0317"/>
                    <measurement group_id="O2" value="1.422" spread="0.0403"/>
                    <measurement group_id="O3" value="1.520" spread="0.0395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 3 (n=124, 64, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.614" spread="0.0303"/>
                    <measurement group_id="O2" value="1.442" spread="0.0391"/>
                    <measurement group_id="O3" value="1.555" spread="0.0380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 4 (n=124, 64, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.577" spread="0.0304"/>
                    <measurement group_id="O2" value="1.416" spread="0.0384"/>
                    <measurement group_id="O3" value="1.519" spread="0.0377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 23, minute 15 (n=120, 55, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.477" spread="0.0323"/>
                    <measurement group_id="O2" value="1.374" spread="0.0422"/>
                    <measurement group_id="O3" value="1.416" spread="0.0399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 23, minute 45 (n=117, 56, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.483" spread="0.0296"/>
                    <measurement group_id="O2" value="1.401" spread="0.0395"/>
                    <measurement group_id="O3" value="1.405" spread="0.0376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, minute 5 (n=125, 62, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.515" spread="0.0293"/>
                    <measurement group_id="O2" value="1.359" spread="0.0385"/>
                    <measurement group_id="O3" value="1.407" spread="0.0372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, minute 15 (n=123, 62, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.529" spread="0.0300"/>
                    <measurement group_id="O2" value="1.360" spread="0.0394"/>
                    <measurement group_id="O3" value="1.425" spread="0.0379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, minute 30 (n=125, 62, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.567" spread="0.0302"/>
                    <measurement group_id="O2" value="1.353" spread="0.0398"/>
                    <measurement group_id="O3" value="1.452" spread="0.0385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, hour 1 (n=125, 62, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.557" spread="0.0285"/>
                    <measurement group_id="O2" value="1.352" spread="0.0376"/>
                    <measurement group_id="O3" value="1.472" spread="0.0361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42, minute 5 (n=119, 61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.512" spread="0.0305"/>
                    <measurement group_id="O2" value="1.394" spread="0.0401"/>
                    <measurement group_id="O3" value="1.490" spread="0.0394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42, minute 15 (n=123, 61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.520" spread="0.0305"/>
                    <measurement group_id="O2" value="1.412" spread="0.0403"/>
                    <measurement group_id="O3" value="1.491" spread="0.0396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42, minute 30 (n=123, 61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.537" spread="0.0332"/>
                    <measurement group_id="O2" value="1.391" spread="0.0431"/>
                    <measurement group_id="O3" value="1.517" spread="0.0424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50, minute 5 (n=120, 60, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.490" spread="0.0269"/>
                    <measurement group_id="O2" value="1.357" spread="0.0348"/>
                    <measurement group_id="O3" value="1.422" spread="0.0341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50, minute 15 (n=123, 60, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.529" spread="0.0285"/>
                    <measurement group_id="O2" value="1.375" spread="0.0369"/>
                    <measurement group_id="O3" value="1.452" spread="0.0362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50, minute 30 (n=123, 60, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.545" spread="0.0287"/>
                    <measurement group_id="O2" value="1.368" spread="0.0375"/>
                    <measurement group_id="O3" value="1.470" spread="0.0366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, minute 5 (n=124, 60, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.456" spread="0.0276"/>
                    <measurement group_id="O2" value="1.337" spread="0.0368"/>
                    <measurement group_id="O3" value="1.377" spread="0.0359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, minute 15 (n=122, 59, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.502" spread="0.0282"/>
                    <measurement group_id="O2" value="1.380" spread="0.0378"/>
                    <measurement group_id="O3" value="1.428" spread="0.0364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, minute 30 (n=125, 62, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.483" spread="0.0280"/>
                    <measurement group_id="O2" value="1.366" spread="0.0370"/>
                    <measurement group_id="O3" value="1.407" spread="0.0362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 1 (n=125, 62, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.525" spread="0.0271"/>
                    <measurement group_id="O2" value="1.356" spread="0.0359"/>
                    <measurement group_id="O3" value="1.439" spread="0.0352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 2 (n=124, 61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.554" spread="0.0295"/>
                    <measurement group_id="O2" value="1.418" spread="0.0393"/>
                    <measurement group_id="O3" value="1.479" spread="0.0382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 3 (n=123, 62, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.558" spread="0.0263"/>
                    <measurement group_id="O2" value="1.384" spread="0.0349"/>
                    <measurement group_id="O3" value="1.487" spread="0.0345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 4 (n=121, 60, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.535" spread="0.0297"/>
                    <measurement group_id="O2" value="1.381" spread="0.0395"/>
                    <measurement group_id="O3" value="1.468" spread="0.0390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 6 (n=118, 59, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.494" spread="0.0294"/>
                    <measurement group_id="O2" value="1.370" spread="0.0392"/>
                    <measurement group_id="O3" value="1.461" spread="0.0388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 8 (n=119, 59, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.473" spread="0.0300"/>
                    <measurement group_id="O2" value="1.358" spread="0.0398"/>
                    <measurement group_id="O3" value="1.418" spread="0.0394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 10 (n=119, 59, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.478" spread="0.0304"/>
                    <measurement group_id="O2" value="1.349" spread="0.0397"/>
                    <measurement group_id="O3" value="1.419" spread="0.0391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 12 (n=120, 58, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.451" spread="0.0334"/>
                    <measurement group_id="O2" value="1.369" spread="0.0446"/>
                    <measurement group_id="O3" value="1.347" spread="0.0444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 16 (n=117, 53, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.377" spread="0.0309"/>
                    <measurement group_id="O2" value="1.277" spread="0.0422"/>
                    <measurement group_id="O3" value="1.329" spread="0.0420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 22 (n=118, 60, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.391" spread="0.0302"/>
                    <measurement group_id="O2" value="1.314" spread="0.0397"/>
                    <measurement group_id="O3" value="1.282" spread="0.0396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 23, 15 minutes (n=121, 62, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.447" spread="0.0287"/>
                    <measurement group_id="O2" value="1.362" spread="0.0378"/>
                    <measurement group_id="O3" value="1.387" spread="0.0371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 23, 45 minutes (n=122, 61, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.434" spread="0.0281"/>
                    <measurement group_id="O2" value="1.337" spread="0.0372"/>
                    <measurement group_id="O3" value="1.359" spread="0.0364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) 5, 15, and 30 Minutes; 1, 2, 3, 4, 6, 8, 10, and 12 Hours; 23 Hours 15 Minutes; and 23 Hours 45 Minutes Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</title>
        <description>Just prior to FVC measurement, patients performed normal tidal breathing. The patient was given a few breaths warning before being told “At the end of the next normal breath out, take a deep breath all the way in”; they were then verbally encouraged to make a maximal effort before relaxing. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.</description>
        <time_frame>5, 15, and 30 minutes; 1, 2, 3, 4, 6, 8, 10, and 12 hours; 23 hours 15 minutes; and 23 hours 45 minutes post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</time_frame>
        <population>Full Analysis Set (FAS), serial spirometry subgroup: A subgroup of approximately one third of all randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) 5, 15, and 30 Minutes; 1, 2, 3, 4, 6, 8, 10, and 12 Hours; 23 Hours 15 Minutes; and 23 Hours 45 Minutes Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</title>
          <description>Just prior to FVC measurement, patients performed normal tidal breathing. The patient was given a few breaths warning before being told “At the end of the next normal breath out, take a deep breath all the way in”; they were then verbally encouraged to make a maximal effort before relaxing. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.</description>
          <population>Full Analysis Set (FAS), serial spirometry subgroup: A subgroup of approximately one third of all randomized patients who received at least 1 dose of study medication.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, minute 5 (n=135, 74, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.027" spread="0.0304"/>
                    <measurement group_id="O2" value="2.826" spread="0.0363"/>
                    <measurement group_id="O3" value="2.956" spread="0.0363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, minute 15 (n=139, 75, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.050" spread="0.0335"/>
                    <measurement group_id="O2" value="2.802" spread="0.0403"/>
                    <measurement group_id="O3" value="2.991" spread="0.0406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, minute 30 (n=143, 77, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.055" spread="0.0343"/>
                    <measurement group_id="O2" value="2.752" spread="0.0416"/>
                    <measurement group_id="O3" value="2.979" spread="0.0422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 1 (n=144, 76, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.148" spread="0.0377"/>
                    <measurement group_id="O2" value="2.791" spread="0.0460"/>
                    <measurement group_id="O3" value="3.041" spread="0.0463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 2 (n=144, 75, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.179" spread="0.0373"/>
                    <measurement group_id="O2" value="2.802" spread="0.0460"/>
                    <measurement group_id="O3" value="3.049" spread="0.0461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 3 (n=143, 74, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.190" spread="0.0433"/>
                    <measurement group_id="O2" value="2.826" spread="0.0526"/>
                    <measurement group_id="O3" value="3.119" spread="0.0531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 4 (n=144, 70, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.138" spread="0.0414"/>
                    <measurement group_id="O2" value="2.783" spread="0.0515"/>
                    <measurement group_id="O3" value="3.102" spread="0.0512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 6 (n=142, 71, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.173" spread="0.0419"/>
                    <measurement group_id="O2" value="2.846" spread="0.0514"/>
                    <measurement group_id="O3" value="3.148" spread="0.0513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 8 (n=137, 70, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.071" spread="0.0404"/>
                    <measurement group_id="O2" value="2.804" spread="0.0506"/>
                    <measurement group_id="O3" value="3.074" spread="0.0498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, hour 10 (n=134, 72, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.134" spread="0.0414"/>
                    <measurement group_id="O2" value="2.865" spread="0.0514"/>
                    <measurement group_id="O3" value="3.119" spread="0.0510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 12 (n=130, 69, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.030" spread="0.0444"/>
                    <measurement group_id="O2" value="2.709" spread="0.0535"/>
                    <measurement group_id="O3" value="3.012" spread="0.0537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 23, minute 15 (n=129, 71, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.991" spread="0.0385"/>
                    <measurement group_id="O2" value="2.800" spread="0.0478"/>
                    <measurement group_id="O3" value="2.988" spread="0.0471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 23, minute 45 (n=128, 74, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.014" spread="0.0364"/>
                    <measurement group_id="O2" value="2.817" spread="0.0444"/>
                    <measurement group_id="O3" value="2.994" spread="0.0442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, minute 5 (n=135, 65, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.051" spread="0.0439"/>
                    <measurement group_id="O2" value="2.793" spread="0.0553"/>
                    <measurement group_id="O3" value="3.014" spread="0.0534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, minute 15 (n=133, 70, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.103" spread="0.0443"/>
                    <measurement group_id="O2" value="2.790" spread="0.0536"/>
                    <measurement group_id="O3" value="3.103" spread="0.0536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, minute 30 (n= 139, 70, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.134" spread="0.0420"/>
                    <measurement group_id="O2" value="2.825" spread="0.0519"/>
                    <measurement group_id="O3" value="3.078" spread="0.0513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, hour 1 (n=140, 68, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.152" spread="0.0434"/>
                    <measurement group_id="O2" value="2.770" spread="0.0537"/>
                    <measurement group_id="O3" value="3.060" spread="0.0528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, minute 5 (n=134, 66, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.139" spread="0.0430"/>
                    <measurement group_id="O2" value="2.866" spread="0.0551"/>
                    <measurement group_id="O3" value="3.071" spread="0.0534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, minute 15 (n=136, 67, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.165" spread="0.0501"/>
                    <measurement group_id="O2" value="2.850" spread="0.0611"/>
                    <measurement group_id="O3" value="3.092" spread="0.0602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, minute 30 (n=135, 67, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.248" spread="0.0540"/>
                    <measurement group_id="O2" value="2.884" spread="0.0644"/>
                    <measurement group_id="O3" value="3.180" spread="0.0636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, minute 5 (n=128, 66, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.195" spread="0.0543"/>
                    <measurement group_id="O2" value="2.826" spread="0.0644"/>
                    <measurement group_id="O3" value="3.097" spread="0.0632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, minute 15 (n=130, 66, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.167" spread="0.0507"/>
                    <measurement group_id="O2" value="2.823" spread="0.0615"/>
                    <measurement group_id="O3" value="3.101" spread="0.0603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, minute 30 (n=130, 67, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.231" spread="0.0567"/>
                    <measurement group_id="O2" value="2.821" spread="0.0675"/>
                    <measurement group_id="O3" value="3.149" spread="0.0664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, minute 5 (n=130, 69, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.060" spread="0.0492"/>
                    <measurement group_id="O2" value="2.728" spread="0.0596"/>
                    <measurement group_id="O3" value="3.023" spread="0.0596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, minute 15 (n=129, 67, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.081" spread="0.0482"/>
                    <measurement group_id="O2" value="2.740" spread="0.0588"/>
                    <measurement group_id="O3" value="3.018" spread="0.0593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, minute 30 (n=133, 69, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.058" spread="0.0479"/>
                    <measurement group_id="O2" value="2.696" spread="0.0585"/>
                    <measurement group_id="O3" value="3.027" spread="0.0591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 1 (n=132, 67, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.164" spread="0.0543"/>
                    <measurement group_id="O2" value="2.737" spread="0.0663"/>
                    <measurement group_id="O3" value="3.098" spread="0.0655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 2 (n=129, 65, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.190" spread="0.0526"/>
                    <measurement group_id="O2" value="2.784" spread="0.0664"/>
                    <measurement group_id="O3" value="3.155" spread="0.0649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 3 (n=126, 64, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.240" spread="0.0569"/>
                    <measurement group_id="O2" value="2.864" spread="0.0713"/>
                    <measurement group_id="O3" value="3.146" spread="0.0685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 4 (n=124, 64, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.119" spread="0.0576"/>
                    <measurement group_id="O2" value="2.745" spread="0.0714"/>
                    <measurement group_id="O3" value="3.084" spread="0.0686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 6 (n=123, 63, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.158" spread="0.0594"/>
                    <measurement group_id="O2" value="2.852" spread="0.0731"/>
                    <measurement group_id="O3" value="3.120" spread="0.0700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 8 (n=121, 64, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.083" spread="0.0534"/>
                    <measurement group_id="O2" value="2.760" spread="0.0657"/>
                    <measurement group_id="O3" value="3.011" spread="0.0644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 10 (n=124, 61, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.130" spread="0.0581"/>
                    <measurement group_id="O2" value="2.860" spread="0.0722"/>
                    <measurement group_id="O3" value="3.117" spread="0.0692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 12 (n=122, 58, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.072" spread="0.0599"/>
                    <measurement group_id="O2" value="2.771" spread="0.0770"/>
                    <measurement group_id="O3" value="3.020" spread="0.0722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 16 (n=109, 56, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.933" spread="0.0645"/>
                    <measurement group_id="O2" value="2.701" spread="0.0800"/>
                    <measurement group_id="O3" value="2.880" spread="0.0785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 22 (n=117, 60, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.924" spread="0.0517"/>
                    <measurement group_id="O2" value="2.673" spread="0.0647"/>
                    <measurement group_id="O3" value="2.870" spread="0.0629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 23, minute 15 (n=126, 66, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.091" spread="0.0548"/>
                    <measurement group_id="O2" value="2.862" spread="0.0676"/>
                    <measurement group_id="O3" value="3.110" spread="0.0671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 23, minute 45 (n=124, 65, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.055" spread="0.0507"/>
                    <measurement group_id="O2" value="2.826" spread="0.0630"/>
                    <measurement group_id="O3" value="3.004" spread="0.0638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, minute 5 (n=123, 65, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.156" spread="0.0608"/>
                    <measurement group_id="O2" value="2.864" spread="0.0719"/>
                    <measurement group_id="O3" value="3.104" spread="0.0723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, minute 15 (n=124, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.156" spread="0.0576"/>
                    <measurement group_id="O2" value="2.801" spread="0.0695"/>
                    <measurement group_id="O3" value="3.082" spread="0.0699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, minute 30 (n=125, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.198" spread="0.0552"/>
                    <measurement group_id="O2" value="2.815" spread="0.0676"/>
                    <measurement group_id="O3" value="3.112" spread="0.0679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20, minute 5 (n=125, 66, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.093" spread="0.0526"/>
                    <measurement group_id="O2" value="2.781" spread="0.0630"/>
                    <measurement group_id="O3" value="2.993" spread="0.0643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20, minute 15 (n=124, 65, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.112" spread="0.0545"/>
                    <measurement group_id="O2" value="2.770" spread="0.0655"/>
                    <measurement group_id="O3" value="3.029" spread="0.0666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20, minute 30 (n=125, 65, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.157" spread="0.0559"/>
                    <measurement group_id="O2" value="2.778" spread="0.0677"/>
                    <measurement group_id="O3" value="3.050" spread="0.0688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, minute 5 (n=123, 62, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.994" spread="0.0528"/>
                    <measurement group_id="O2" value="2.700" spread="0.0670"/>
                    <measurement group_id="O3" value="2.954" spread="0.0658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, minute 15 (n=121, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.041" spread="0.0513"/>
                    <measurement group_id="O2" value="2.692" spread="0.0652"/>
                    <measurement group_id="O3" value="2.976" spread="0.0644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, minute 30 (n=125, 64, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.054" spread="0.0464"/>
                    <measurement group_id="O2" value="2.700" spread="0.0597"/>
                    <measurement group_id="O3" value="2.994" spread="0.0589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 1 (n=127, 64, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.077" spread="0.0520"/>
                    <measurement group_id="O2" value="2.678" spread="0.0658"/>
                    <measurement group_id="O3" value="3.016" spread="0.0651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 2 (n=124, 64, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.110" spread="0.0516"/>
                    <measurement group_id="O2" value="2.771" spread="0.0655"/>
                    <measurement group_id="O3" value="3.080" spread="0.0650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 3 (n=124, 64, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.210" spread="0.0648"/>
                    <measurement group_id="O2" value="2.871" spread="0.0765"/>
                    <measurement group_id="O3" value="3.176" spread="0.0762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 4 (n=124, 64, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.111" spread="0.0551"/>
                    <measurement group_id="O2" value="2.791" spread="0.0664"/>
                    <measurement group_id="O3" value="3.086" spread="0.0664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 23, minute 15 (n=120, 55, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.056" spread="0.0600"/>
                    <measurement group_id="O2" value="2.803" spread="0.0749"/>
                    <measurement group_id="O3" value="2.932" spread="0.0721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 23, minute 45 (n=117, 56, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.998" spread="0.0512"/>
                    <measurement group_id="O2" value="2.752" spread="0.0667"/>
                    <measurement group_id="O3" value="2.895" spread="0.0646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, minute 5 (n=125, 62, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.023" spread="0.0573"/>
                    <measurement group_id="O2" value="2.731" spread="0.0715"/>
                    <measurement group_id="O3" value="2.881" spread="0.0706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, minute 15 (n=123, 62, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.016" spread="0.0553"/>
                    <measurement group_id="O2" value="2.731" spread="0.0691"/>
                    <measurement group_id="O3" value="2.898" spread="0.0683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, minute 30 (n=125, 62, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.081" spread="0.0555"/>
                    <measurement group_id="O2" value="2.687" spread="0.0715"/>
                    <measurement group_id="O3" value="2.971" spread="0.0708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, hour 1 (n=125, 62, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.072" spread="0.0564"/>
                    <measurement group_id="O2" value="2.703" spread="0.0707"/>
                    <measurement group_id="O3" value="2.963" spread="0.0699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42, minute 5 (n=119, 61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.033" spread="0.0583"/>
                    <measurement group_id="O2" value="2.716" spread="0.0744"/>
                    <measurement group_id="O3" value="3.069" spread="0.0746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42, minute 15 (n=123, 61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.022" spread="0.0539"/>
                    <measurement group_id="O2" value="2.695" spread="0.0706"/>
                    <measurement group_id="O3" value="3.065" spread="0.0699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42, minute 30 (n=123, 61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.057" spread="0.0565"/>
                    <measurement group_id="O2" value="2.723" spread="0.0734"/>
                    <measurement group_id="O3" value="3.098" spread="0.0734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50, minute 5 (n=120, 60, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.022" spread="0.0596"/>
                    <measurement group_id="O2" value="2.731" spread="0.0727"/>
                    <measurement group_id="O3" value="2.963" spread="0.0726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50, minute 15 (n=123, 60, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.042" spread="0.0592"/>
                    <measurement group_id="O2" value="2.702" spread="0.0726"/>
                    <measurement group_id="O3" value="2.937" spread="0.0725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50, minute 30 (n=123, 60, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.094" spread="0.0613"/>
                    <measurement group_id="O2" value="2.731" spread="0.0749"/>
                    <measurement group_id="O3" value="2.985" spread="0.0747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, minute 5 (n=124, 60, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.940" spread="0.0551"/>
                    <measurement group_id="O2" value="2.645" spread="0.0701"/>
                    <measurement group_id="O3" value="2.860" spread="0.0702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, minute 15 (n=122, 59, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.960" spread="0.0518"/>
                    <measurement group_id="O2" value="2.640" spread="0.0675"/>
                    <measurement group_id="O3" value="2.935" spread="0.0666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, minute 30 (n=125, 62, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.939" spread="0.0499"/>
                    <measurement group_id="O2" value="2.625" spread="0.0650"/>
                    <measurement group_id="O3" value="2.929" spread="0.0652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 1 (n=125, 62, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.031" spread="0.0564"/>
                    <measurement group_id="O2" value="2.617" spread="0.0698"/>
                    <measurement group_id="O3" value="2.980" spread="0.0704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 2 (n=124, 61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.062" spread="0.0556"/>
                    <measurement group_id="O2" value="2.714" spread="0.0689"/>
                    <measurement group_id="O3" value="3.021" spread="0.0689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 3 (n=123, 62, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.108" spread="0.0648"/>
                    <measurement group_id="O2" value="2.716" spread="0.0766"/>
                    <measurement group_id="O3" value="3.053" spread="0.0779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 4 (n=121, 60, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.021" spread="0.0585"/>
                    <measurement group_id="O2" value="2.694" spread="0.0724"/>
                    <measurement group_id="O3" value="2.978" spread="0.0735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 6 (n=118, 59, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.986" spread="0.0614"/>
                    <measurement group_id="O2" value="2.690" spread="0.0770"/>
                    <measurement group_id="O3" value="2.982" spread="0.0781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 8 (n=119, 59, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.961" spread="0.0646"/>
                    <measurement group_id="O2" value="2.637" spread="0.0793"/>
                    <measurement group_id="O3" value="2.942" spread="0.0805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 10 (n=119, 59, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.000" spread="0.0701"/>
                    <measurement group_id="O2" value="2.687" spread="0.0840"/>
                    <measurement group_id="O3" value="3.012" spread="0.0844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 12 (n=120, 58, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.881" spread="0.0631"/>
                    <measurement group_id="O2" value="2.636" spread="0.0831"/>
                    <measurement group_id="O3" value="2.849" spread="0.0847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 16 (n=117, 53, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.857" spread="0.0694"/>
                    <measurement group_id="O2" value="2.542" spread="0.0857"/>
                    <measurement group_id="O3" value="2.772" spread="0.0873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 22 (n=118, 60, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.812" spread="0.0670"/>
                    <measurement group_id="O2" value="2.604" spread="0.0810"/>
                    <measurement group_id="O3" value="2.716" spread="0.0827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 23, 15 minutes (n=121, 62, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.888" spread="0.0595"/>
                    <measurement group_id="O2" value="2.678" spread="0.0751"/>
                    <measurement group_id="O3" value="2.852" spread="0.0755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 23, 45 minutes (n=122, 61, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.855" spread="0.0558"/>
                    <measurement group_id="O2" value="2.607" spread="0.0700"/>
                    <measurement group_id="O3" value="2.797" spread="0.0702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) 5, 15, and 30 Minutes; and 1, 2, 3, and 4 Hours Post Dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</title>
        <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.</description>
        <time_frame>5, 15, and 30 minutes; and 1, 2, 3, 4 hours post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) 5, 15, and 30 Minutes; and 1, 2, 3, and 4 Hours Post Dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</title>
          <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="268"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, minute 5 (n=495, 255, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.443" spread="0.0067"/>
                    <measurement group_id="O2" value="1.357" spread="0.0081"/>
                    <measurement group_id="O3" value="1.402" spread="0.0081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, minute 15 (n=502, 255, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.501" spread="0.0074"/>
                    <measurement group_id="O2" value="1.359" spread="0.0090"/>
                    <measurement group_id="O3" value="1.437" spread="0.0090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, minute 30 (n=507, 252, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.524" spread="0.0103"/>
                    <measurement group_id="O2" value="1.357" spread="0.0126"/>
                    <measurement group_id="O3" value="1.468" spread="0.0125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 1 (n=511, 256, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.552" spread="0.0082"/>
                    <measurement group_id="O2" value="1.353" spread="0.0101"/>
                    <measurement group_id="O3" value="1.484" spread="0.0101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 2 (n=513, 253, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.612" spread="0.0090"/>
                    <measurement group_id="O2" value="1.397" spread="0.0113"/>
                    <measurement group_id="O3" value="1.549" spread="0.0112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 3 (n=510, 248, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.590" spread="0.0088"/>
                    <measurement group_id="O2" value="1.389" spread="0.0111"/>
                    <measurement group_id="O3" value="1.560" spread="0.0109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 4 (n=504, 239, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.590" spread="0.0095"/>
                    <measurement group_id="O2" value="1.396" spread="0.0121"/>
                    <measurement group_id="O3" value="1.549" spread="0.0117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 23, minute 15 (n=481, 243, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.459" spread="0.0093"/>
                    <measurement group_id="O2" value="1.364" spread="0.0115"/>
                    <measurement group_id="O3" value="1.457" spread="0.0115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 23, minute 45 (n=474, 239, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.482" spread="0.0094"/>
                    <measurement group_id="O2" value="1.390" spread="0.0117"/>
                    <measurement group_id="O3" value="1.473" spread="0.0118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, minute 5 (n=498, 223, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.491" spread="0.0123"/>
                    <measurement group_id="O2" value="1.368" spread="0.0157"/>
                    <measurement group_id="O3" value="1.472" spread="0.0151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, minute 15 (n=487, 229, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.527" spread="0.0123"/>
                    <measurement group_id="O2" value="1.371" spread="0.0154"/>
                    <measurement group_id="O3" value="1.514" spread="0.0151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, minute 30 (n=503, 233, 242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.538" spread="0.0122"/>
                    <measurement group_id="O2" value="1.368" spread="0.0152"/>
                    <measurement group_id="O3" value="1.504" spread="0.0150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, hour 1 (n=501, 229, 240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.561" spread="0.0121"/>
                    <measurement group_id="O2" value="1.379" spread="0.0153"/>
                    <measurement group_id="O3" value="1.525" spread="0.0150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, minute 5 (n=476, 221, 231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.509" spread="0.0125"/>
                    <measurement group_id="O2" value="1.371" spread="0.0161"/>
                    <measurement group_id="O3" value="1.488" spread="0.0157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, minute 15 (n=479, 222, 234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.538" spread="0.0126"/>
                    <measurement group_id="O2" value="1.389" spread="0.0162"/>
                    <measurement group_id="O3" value="1.508" spread="0.0157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, minute 30 (n=480, 223, 234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.564" spread="0.0129"/>
                    <measurement group_id="O2" value="1.396" spread="0.0165"/>
                    <measurement group_id="O3" value="1.525" spread="0.0160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, minute 5 (n=454, 217, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.529" spread="0.0126"/>
                    <measurement group_id="O2" value="1.366" spread="0.0159"/>
                    <measurement group_id="O3" value="1.499" spread="0.0157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, minute 15 (n=459, 220, 225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.550" spread="0.0132"/>
                    <measurement group_id="O2" value="1.376" spread="0.0164"/>
                    <measurement group_id="O3" value="1.515" spread="0.0163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, minute 30 (n=460, 220, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.569" spread="0.0125"/>
                    <measurement group_id="O2" value="1.378" spread="0.0158"/>
                    <measurement group_id="O3" value="1.531" spread="0.0157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, minute 5 (n=453, 212, 230)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.502" spread="0.0136"/>
                    <measurement group_id="O2" value="1.349" spread="0.0173"/>
                    <measurement group_id="O3" value="1.477" spread="0.0167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, minute 15 (n=448, 205, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.527" spread="0.0131"/>
                    <measurement group_id="O2" value="1.352" spread="0.0171"/>
                    <measurement group_id="O3" value="1.501" spread="0.0166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, minute 30 (n=455, 212, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.522" spread="0.0139"/>
                    <measurement group_id="O2" value="1.352" spread="0.0176"/>
                    <measurement group_id="O3" value="1.491" spread="0.0170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 1 (n=455, 210, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.556" spread="0.0139"/>
                    <measurement group_id="O2" value="1.364" spread="0.0178"/>
                    <measurement group_id="O3" value="1.528" spread="0.0171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 2 (n=446, 207, 225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.595" spread="0.0145"/>
                    <measurement group_id="O2" value="1.423" spread="0.0185"/>
                    <measurement group_id="O3" value="1.558" spread="0.0178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 3 (n=444, 204, 225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.592" spread="0.0145"/>
                    <measurement group_id="O2" value="1.414" spread="0.0186"/>
                    <measurement group_id="O3" value="1.561" spread="0.0177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 4 (n=437, 202, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.558" spread="0.0152"/>
                    <measurement group_id="O2" value="1.416" spread="0.0193"/>
                    <measurement group_id="O3" value="1.534" spread="0.0183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 23, minute 15 (n=430, 200, 214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.481" spread="0.0143"/>
                    <measurement group_id="O2" value="1.381" spread="0.0183"/>
                    <measurement group_id="O3" value="1.457" spread="0.0177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 23, minute 45 (n=426, 195, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.493" spread="0.0149"/>
                    <measurement group_id="O2" value="1.413" spread="0.0190"/>
                    <measurement group_id="O3" value="1.472" spread="0.0187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, minute 5 (n=429, 207, 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.514" spread="0.0151"/>
                    <measurement group_id="O2" value="1.373" spread="0.0185"/>
                    <measurement group_id="O3" value="1.487" spread="0.0181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, minute 15 (n=428, 209, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.530" spread="0.0155"/>
                    <measurement group_id="O2" value="1.372" spread="0.0189"/>
                    <measurement group_id="O3" value="1.491" spread="0.0186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, minute 30 (n=433, 209, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.546" spread="0.0160"/>
                    <measurement group_id="O2" value="1.372" spread="0.0194"/>
                    <measurement group_id="O3" value="1.505" spread="0.0190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20, minute 5 (n=430, 206, 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.495" spread="0.0159"/>
                    <measurement group_id="O2" value="1.351" spread="0.0198"/>
                    <measurement group_id="O3" value="1.464" spread="0.0192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20, minute 15 (n=430, 207, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.525" spread="0.0164"/>
                    <measurement group_id="O2" value="1.362" spread="0.0203"/>
                    <measurement group_id="O3" value="1.495" spread="0.0196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20, minute 30 (n=431, 207, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.544" spread="0.0164"/>
                    <measurement group_id="O2" value="1.362" spread="0.0203"/>
                    <measurement group_id="O3" value="1.498" spread="0.0195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, minute 5 (421, 202, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.479" spread="0.0153"/>
                    <measurement group_id="O2" value="1.339" spread="0.0189"/>
                    <measurement group_id="O3" value="1.429" spread="0.0185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, minute 15 (n=414, 200, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.504" spread="0.0155"/>
                    <measurement group_id="O2" value="1.340" spread="0.0193"/>
                    <measurement group_id="O3" value="1.458" spread="0.0191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, minute 30 (n=424, 206, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.513" spread="0.0161"/>
                    <measurement group_id="O2" value="1.341" spread="0.0196"/>
                    <measurement group_id="O3" value="1.451" spread="0.0193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 1 (n=425, 206, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.541" spread="0.0160"/>
                    <measurement group_id="O2" value="1.345" spread="0.0193"/>
                    <measurement group_id="O3" value="1.487" spread="0.0190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 2 (n=420, 203, 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.570" spread="0.0176"/>
                    <measurement group_id="O2" value="1.388" spread="0.0212"/>
                    <measurement group_id="O3" value="1.524" spread="0.0210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 3 (n=416, 204, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.570" spread="0.0181"/>
                    <measurement group_id="O2" value="1.398" spread="0.0216"/>
                    <measurement group_id="O3" value="1.526" spread="0.0211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 4 (n=416, 203, 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.547" spread="0.0175"/>
                    <measurement group_id="O2" value="1.384" spread="0.0211"/>
                    <measurement group_id="O3" value="1.504" spread="0.0208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 23, minute 15 (n=405, 187, 202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.464" spread="0.0175"/>
                    <measurement group_id="O2" value="1.326" spread="0.0217"/>
                    <measurement group_id="O3" value="1.415" spread="0.0212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 23, minute 45 (n=401, 185, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.474" spread="0.0175"/>
                    <measurement group_id="O2" value="1.354" spread="0.0218"/>
                    <measurement group_id="O3" value="1.426" spread="0.0215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, minute 5 (n=408, 194, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.481" spread="0.0167"/>
                    <measurement group_id="O2" value="1.338" spread="0.0210"/>
                    <measurement group_id="O3" value="1.422" spread="0.0202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, minute 15 (n=407, 191, 214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.508" spread="0.0172"/>
                    <measurement group_id="O2" value="1.333" spread="0.0215"/>
                    <measurement group_id="O3" value="1.443" spread="0.0206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, minute 30 (n=410, 196, 215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.518" spread="0.0172"/>
                    <measurement group_id="O2" value="1.331" spread="0.0214"/>
                    <measurement group_id="O3" value="1.444" spread="0.0206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, hour 1 (n=412, 195, 215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.534" spread="0.0171"/>
                    <measurement group_id="O2" value="1.331" spread="0.0213"/>
                    <measurement group_id="O3" value="1.464" spread="0.0205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42, minute 5 (n=398, 189, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.489" spread="0.0172"/>
                    <measurement group_id="O2" value="1.342" spread="0.0218"/>
                    <measurement group_id="O3" value="1.459" spread="0.0213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42, minute 15 (n=405, 188, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.511" spread="0.0171"/>
                    <measurement group_id="O2" value="1.344" spread="0.0218"/>
                    <measurement group_id="O3" value="1.477" spread="0.0211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42, minute 30 (n=405, 189, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.518" spread="0.0183"/>
                    <measurement group_id="O2" value="1.350" spread="0.0229"/>
                    <measurement group_id="O3" value="1.496" spread="0.0222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50, minute 5 (n=386, 185, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.454" spread="0.0155"/>
                    <measurement group_id="O2" value="1.336" spread="0.0197"/>
                    <measurement group_id="O3" value="1.429" spread="0.0190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50, minute 15 (n=391, 187, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.496" spread="0.0156"/>
                    <measurement group_id="O2" value="1.341" spread="0.0199"/>
                    <measurement group_id="O3" value="1.462" spread="0.0192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50, minute 30 (n=392, 186, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.504" spread="0.0166"/>
                    <measurement group_id="O2" value="1.341" spread="0.0210"/>
                    <measurement group_id="O3" value="1.475" spread="0.0200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, minute 5 (n=401, 188, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.436" spread="0.0155"/>
                    <measurement group_id="O2" value="1.305" spread="0.0200"/>
                    <measurement group_id="O3" value="1.419" spread="0.0195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, minute 15 (n=394, 183, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.471" spread="0.0159"/>
                    <measurement group_id="O2" value="1.323" spread="0.0208"/>
                    <measurement group_id="O3" value="1.451" spread="0.0198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, minute 30 (n=402, 189, 202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.471" spread="0.0164"/>
                    <measurement group_id="O2" value="1.319" spread="0.0209"/>
                    <measurement group_id="O3" value="1.451" spread="0.0202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 1 (n=404, 190, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.499" spread="0.0161"/>
                    <measurement group_id="O2" value="1.325" spread="0.0205"/>
                    <measurement group_id="O3" value="1.482" spread="0.0198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 2 (n=402, 186, 202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.526" spread="0.0177"/>
                    <measurement group_id="O2" value="1.363" spread="0.0224"/>
                    <measurement group_id="O3" value="1.511" spread="0.0214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 3 (n=400, 186, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.525" spread="0.0171"/>
                    <measurement group_id="O2" value="1.344" spread="0.0215"/>
                    <measurement group_id="O3" value="1.509" spread="0.0207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 4 (n=397, 184, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.504" spread="0.0176"/>
                    <measurement group_id="O2" value="1.346" spread="0.0222"/>
                    <measurement group_id="O3" value="1.501" spread="0.0213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 23, minute 15 (n=388, 183, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.419" spread="0.0169"/>
                    <measurement group_id="O2" value="1.303" spread="0.0215"/>
                    <measurement group_id="O3" value="1.397" spread="0.0205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 23, minute 45 (n=395, 185, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.424" spread="0.0165"/>
                    <measurement group_id="O2" value="1.320" spread="0.0210"/>
                    <measurement group_id="O3" value="1.411" spread="0.0201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) 5, 15, and 30 Minutes; and 1, 2, 3, and 4 Hours Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</title>
        <description>Just prior to FVC measurement, patients performed normal tidal breathing. The patient was given a few breaths warning before being told “At the end of the next normal breath out, take a deep breath all the way in”; they were then verbally encouraged to make a maximal effort before relaxing. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.</description>
        <time_frame>5, 15, and 30 minutes; and 1, 2, 3, 4 hours post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) 5, 15, and 30 Minutes; and 1, 2, 3, and 4 Hours Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52</title>
          <description>Just prior to FVC measurement, patients performed normal tidal breathing. The patient was given a few breaths warning before being told “At the end of the next normal breath out, take a deep breath all the way in”; they were then verbally encouraged to make a maximal effort before relaxing. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="268"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, minute 5 (n=495, 255, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.915" spread="0.0145"/>
                    <measurement group_id="O2" value="2.731" spread="0.0174"/>
                    <measurement group_id="O3" value="2.856" spread="0.0174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, minute 15 (n=502, 255, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.982" spread="0.0164"/>
                    <measurement group_id="O2" value="2.719" spread="0.0199"/>
                    <measurement group_id="O3" value="2.903" spread="0.0198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, minute 30 (n=507, 252, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.004" spread="0.0177"/>
                    <measurement group_id="O2" value="2.692" spread="0.0219"/>
                    <measurement group_id="O3" value="2.937" spread="0.0217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 1 (n=511, 256, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.074" spread="0.0173"/>
                    <measurement group_id="O2" value="2.732" spread="0.0214"/>
                    <measurement group_id="O3" value="2.975" spread="0.0213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 2 (n=513, 253, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.119" spread="0.0182"/>
                    <measurement group_id="O2" value="2.762" spread="0.0227"/>
                    <measurement group_id="O3" value="3.033" spread="0.0226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 3 (n=510, 248, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.129" spread="0.0193"/>
                    <measurement group_id="O2" value="2.811" spread="0.0243"/>
                    <measurement group_id="O3" value="3.073" spread="0.0239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 4 (n=504, 239, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.076" spread="0.0192"/>
                    <measurement group_id="O2" value="2.767" spread="0.0244"/>
                    <measurement group_id="O3" value="3.031" spread="0.0237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 23, minute 15 (n=481, 243, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.926" spread="0.0178"/>
                    <measurement group_id="O2" value="2.745" spread="0.0220"/>
                    <measurement group_id="O3" value="2.923" spread="0.0220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 23, minute 45 (n=474, 239, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.930" spread="0.0178"/>
                    <measurement group_id="O2" value="2.749" spread="0.0221"/>
                    <measurement group_id="O3" value="2.923" spread="0.0224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, minute 5 (n=498, 223, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.984" spread="0.0222"/>
                    <measurement group_id="O2" value="2.760" spread="0.0282"/>
                    <measurement group_id="O3" value="2.980" spread="0.0272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, minute 15 (n=487, 229, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.016" spread="0.0220"/>
                    <measurement group_id="O2" value="2.748" spread="0.0274"/>
                    <measurement group_id="O3" value="3.030" spread="0.0270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, minute 30 (n=503, 233, 242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.028" spread="0.0212"/>
                    <measurement group_id="O2" value="2.756" spread="0.0269"/>
                    <measurement group_id="O3" value="3.018" spread="0.0265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, hour 1 (n=501, 229, 240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.068" spread="0.0213"/>
                    <measurement group_id="O2" value="2.757" spread="0.0271"/>
                    <measurement group_id="O3" value="3.023" spread="0.0267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, minute 5 (n=476, 221, 231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.004" spread="0.0215"/>
                    <measurement group_id="O2" value="2.768" spread="0.0277"/>
                    <measurement group_id="O3" value="3.011" spread="0.0270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, minute 15 (n=479, 222, 234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.024" spread="0.0234"/>
                    <measurement group_id="O2" value="2.771" spread="0.0294"/>
                    <measurement group_id="O3" value="3.024" spread="0.0286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, minute 30 (n=480, 223, 234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.085" spread="0.0243"/>
                    <measurement group_id="O2" value="2.804" spread="0.0305"/>
                    <measurement group_id="O3" value="3.063" spread="0.0297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, minute 5 (n=454, 217, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.047" spread="0.0262"/>
                    <measurement group_id="O2" value="2.767" spread="0.0313"/>
                    <measurement group_id="O3" value="3.029" spread="0.0309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, minute 15 (n=459, 220, 225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.050" spread="0.0257"/>
                    <measurement group_id="O2" value="2.764" spread="0.0312"/>
                    <measurement group_id="O3" value="3.046" spread="0.0311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, minute 30 (n=460, 220, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.079" spread="0.0265"/>
                    <measurement group_id="O2" value="2.768" spread="0.0322"/>
                    <measurement group_id="O3" value="3.079" spread="0.0319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, minute 5 (n=453, 212, 230)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.991" spread="0.0253"/>
                    <measurement group_id="O2" value="2.726" spread="0.0313"/>
                    <measurement group_id="O3" value="2.978" spread="0.0304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, minute 15 (n=448, 205, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.003" spread="0.0252"/>
                    <measurement group_id="O2" value="2.735" spread="0.0316"/>
                    <measurement group_id="O3" value="3.004" spread="0.0307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, minute 30 (n=455, 212, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.985" spread="0.0251"/>
                    <measurement group_id="O2" value="2.707" spread="0.0314"/>
                    <measurement group_id="O3" value="2.987" spread="0.0306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 1 (n=455, 210, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.062" spread="0.0267"/>
                    <measurement group_id="O2" value="2.741" spread="0.0333"/>
                    <measurement group_id="O3" value="3.048" spread="0.0322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 2 (n=446, 207, 225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.093" spread="0.0266"/>
                    <measurement group_id="O2" value="2.801" spread="0.0335"/>
                    <measurement group_id="O3" value="3.065" spread="0.0324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 3 (n=444, 204, 225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.129" spread="0.0275"/>
                    <measurement group_id="O2" value="2.839" spread="0.0346"/>
                    <measurement group_id="O3" value="3.096" spread="0.0332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 4 (n=437, 202, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.050" spread="0.0278"/>
                    <measurement group_id="O2" value="2.793" spread="0.0349"/>
                    <measurement group_id="O3" value="3.054" spread="0.0333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 23, minute 15 (n=430, 200, 214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.991" spread="0.0282"/>
                    <measurement group_id="O2" value="2.799" spread="0.0349"/>
                    <measurement group_id="O3" value="2.985" spread="0.0341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, hour 23, minute 45 (n=426, 195, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.977" spread="0.0268"/>
                    <measurement group_id="O2" value="2.799" spread="0.0336"/>
                    <measurement group_id="O3" value="2.946" spread="0.0332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, minute 5 (n=429, 207, 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.016" spread="0.0301"/>
                    <measurement group_id="O2" value="2.753" spread="0.0362"/>
                    <measurement group_id="O3" value="3.009" spread="0.0355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, minute 15 (n=428, 209, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.029" spread="0.0293"/>
                    <measurement group_id="O2" value="2.737" spread="0.0353"/>
                    <measurement group_id="O3" value="3.002" spread="0.0348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, minute 30 (n=433, 209, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.063" spread="0.0298"/>
                    <measurement group_id="O2" value="2.747" spread="0.0359"/>
                    <measurement group_id="O3" value="3.036" spread="0.0353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20, minute 5 (n=430, 206, 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.985" spread="0.0286"/>
                    <measurement group_id="O2" value="2.744" spread="0.0349"/>
                    <measurement group_id="O3" value="2.966" spread="0.0338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20, minute 15 (n=430, 207, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.020" spread="0.0293"/>
                    <measurement group_id="O2" value="2.749" spread="0.0356"/>
                    <measurement group_id="O3" value="2.994" spread="0.0345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20, minute 30 (n=431, 207, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.058" spread="0.0309"/>
                    <measurement group_id="O2" value="2.774" spread="0.0374"/>
                    <measurement group_id="O3" value="3.028" spread="0.0362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, minute 5 (421, 202, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.956" spread="0.0289"/>
                    <measurement group_id="O2" value="2.733" spread="0.0352"/>
                    <measurement group_id="O3" value="2.945" spread="0.0345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, minute 15 (n=414, 200, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.980" spread="0.0298"/>
                    <measurement group_id="O2" value="2.713" spread="0.0363"/>
                    <measurement group_id="O3" value="2.959" spread="0.0360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, minute 30 (n=424, 206, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.983" spread="0.0282"/>
                    <measurement group_id="O2" value="2.715" spread="0.0342"/>
                    <measurement group_id="O3" value="2.949" spread="0.0337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 1 (n=425, 206, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.034" spread="0.0293"/>
                    <measurement group_id="O2" value="2.721" spread="0.0352"/>
                    <measurement group_id="O3" value="2.997" spread="0.0346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 2 (n=420, 203, 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.049" spread="0.0308"/>
                    <measurement group_id="O2" value="2.777" spread="0.0370"/>
                    <measurement group_id="O3" value="3.036" spread="0.0366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 3 (n=416, 204, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.097" spread="0.0331"/>
                    <measurement group_id="O2" value="2.831" spread="0.0389"/>
                    <measurement group_id="O3" value="3.065" spread="0.0381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 4 (n=416, 203, 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.022" spread="0.0312"/>
                    <measurement group_id="O2" value="2.776" spread="0.0369"/>
                    <measurement group_id="O3" value="3.021" spread="0.0364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 23, minute 15 (n=405, 187, 202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.971" spread="0.0321"/>
                    <measurement group_id="O2" value="2.758" spread="0.0387"/>
                    <measurement group_id="O3" value="2.901" spread="0.0379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26, hour 23, minute 45 (n=401, 185, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.952" spread="0.0305"/>
                    <measurement group_id="O2" value="2.759" spread="0.0373"/>
                    <measurement group_id="O3" value="2.883" spread="0.0368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, minute 5 (n=408, 194, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.967" spread="0.0321"/>
                    <measurement group_id="O2" value="2.713" spread="0.0387"/>
                    <measurement group_id="O3" value="2.919" spread="0.0374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, minute 15 (n=407, 191, 214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.983" spread="0.0327"/>
                    <measurement group_id="O2" value="2.718" spread="0.0392"/>
                    <measurement group_id="O3" value="2.948" spread="0.0376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, minute 30 (n=410, 196, 215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.002" spread="0.0333"/>
                    <measurement group_id="O2" value="2.690" spread="0.0400"/>
                    <measurement group_id="O3" value="2.947" spread="0.0386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, hour 1 (n=412, 195, 215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.014" spread="0.0336"/>
                    <measurement group_id="O2" value="2.711" spread="0.0400"/>
                    <measurement group_id="O3" value="2.959" spread="0.0385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42, minute 5 (n=398, 189, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.982" spread="0.0344"/>
                    <measurement group_id="O2" value="2.727" spread="0.0415"/>
                    <measurement group_id="O3" value="2.983" spread="0.0406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42, minute 15 (n=405, 188, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.001" spread="0.0336"/>
                    <measurement group_id="O2" value="2.713" spread="0.0410"/>
                    <measurement group_id="O3" value="3.001" spread="0.0398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42, minute 30 (n=405, 189, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.016" spread="0.0345"/>
                    <measurement group_id="O2" value="2.734" spread="0.0419"/>
                    <measurement group_id="O3" value="3.021" spread="0.0408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50, minute 5 (n=386, 185, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.925" spread="0.0328"/>
                    <measurement group_id="O2" value="2.729" spread="0.0393"/>
                    <measurement group_id="O3" value="2.942" spread="0.0381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50, minute 15 (n=391, 187, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.971" spread="0.0330"/>
                    <measurement group_id="O2" value="2.729" spread="0.0398"/>
                    <measurement group_id="O3" value="2.962" spread="0.0384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50, minute 30 (n=392, 186, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.999" spread="0.0342"/>
                    <measurement group_id="O2" value="2.731" spread="0.0409"/>
                    <measurement group_id="O3" value="2.998" spread="0.0394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, minute 5 (n=401, 188, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.899" spread="0.0309"/>
                    <measurement group_id="O2" value="2.673" spread="0.0377"/>
                    <measurement group_id="O3" value="2.916" spread="0.0367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, minute 15 (n=394, 183, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.942" spread="0.0314"/>
                    <measurement group_id="O2" value="2.701" spread="0.0389"/>
                    <measurement group_id="O3" value="2.969" spread="0.0371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, minute 30 (n=402, 189, 202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.923" spread="0.0325"/>
                    <measurement group_id="O2" value="2.666" spread="0.0391"/>
                    <measurement group_id="O3" value="2.962" spread="0.0378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 1 (n=404, 190, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.992" spread="0.0339"/>
                    <measurement group_id="O2" value="2.696" spread="0.0405"/>
                    <measurement group_id="O3" value="3.011" spread="0.0393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 2 (n=402, 186, 202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.997" spread="0.0354"/>
                    <measurement group_id="O2" value="2.727" spread="0.0421"/>
                    <measurement group_id="O3" value="3.005" spread="0.0405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 3 (n=400, 186, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.029" spread="0.0359"/>
                    <measurement group_id="O2" value="2.742" spread="0.0427"/>
                    <measurement group_id="O3" value="3.020" spread="0.0413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 4 (n=397, 184, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.984" spread="0.0359"/>
                    <measurement group_id="O2" value="2.725" spread="0.0425"/>
                    <measurement group_id="O3" value="2.991" spread="0.0410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 23, minute 15 (n=388, 183, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.866" spread="0.0349"/>
                    <measurement group_id="O2" value="2.675" spread="0.0419"/>
                    <measurement group_id="O3" value="2.865" spread="0.0402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, hour 23, minute 45 (n=395, 185, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.869" spread="0.0342"/>
                    <measurement group_id="O2" value="2.694" spread="0.0406"/>
                    <measurement group_id="O3" value="2.868" spread="0.0390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose at Day 1 and Weeks 12, 26, and 52</title>
        <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, 3, and 4 hours post-dose. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included the same covariates as the primary Outcome Measure.</description>
        <time_frame>From 5 minutes to 4 hours post-dose at Day 1 and Weeks 12, 26, and 52</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose at Day 1 and Weeks 12, 26, and 52</title>
          <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, 3, and 4 hours post-dose. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included the same covariates as the primary Outcome Measure.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.570" spread="0.0075"/>
                    <measurement group_id="O2" value="1.373" spread="0.0092"/>
                    <measurement group_id="O3" value="1.514" spread="0.0092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=460, 214, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.560" spread="0.0134"/>
                    <measurement group_id="O2" value="1.384" spread="0.0170"/>
                    <measurement group_id="O3" value="1.531" spread="0.0164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=430, 206, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.546" spread="0.0160"/>
                    <measurement group_id="O2" value="1.369" spread="0.0194"/>
                    <measurement group_id="O3" value="1.495" spread="0.0190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=405, 192, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.502" spread="0.0162"/>
                    <measurement group_id="O2" value="1.336" spread="0.0203"/>
                    <measurement group_id="O3" value="1.487" spread="0.0196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 12 Hours Post-dose at Day 1 and Weeks 12 and 52</title>
        <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, 3, 4, 6, 8 10, and 12 hours post-dose. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included the same covariates as the primary Outcome Measure.</description>
        <time_frame>From 5 minutes to 12 hours post-dose at Day 1 and Weeks 12 and 52</time_frame>
        <population>Full Analysis Set (FAS), serial spirometry subgroup: A subgroup of approximately one third of all randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 12 Hours Post-dose at Day 1 and Weeks 12 and 52</title>
          <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, 3, 4, 6, 8 10, and 12 hours post-dose. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included the same covariates as the primary Outcome Measure.</description>
          <population>Full Analysis Set (FAS), serial spirometry subgroup: A subgroup of approximately one third of all randomized patients who received at least 1 dose of study medication.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.566" spread="0.0168"/>
                    <measurement group_id="O2" value="1.407" spread="0.0207"/>
                    <measurement group_id="O3" value="1.534" spread="0.0206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=133, 69, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.539" spread="0.0261"/>
                    <measurement group_id="O2" value="1.398" spread="0.0324"/>
                    <measurement group_id="O3" value="1.505" spread="0.0320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=125, 62, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.492" spread="0.0265"/>
                    <measurement group_id="O2" value="1.364" spread="0.0352"/>
                    <measurement group_id="O3" value="1.424" spread="0.0344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 23 Hours 45 Minutes and From 12 Hours to 23 Hours 45 Minutes Post-dose at Weeks 12 and 52</title>
        <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; 1, 2, 3, 4, 6, 8, 10, and 12 hours; 23 hours 15 minutes; and 23 hours 45 minutes post-dose. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included the same covariates as the primary Outcome Measure.</description>
        <time_frame>From 5 minutes to 23 hours 45 minutes post-dose at Weeks 12 and 52</time_frame>
        <population>Full Analysis Set (FAS), serial spirometry subgroup: A subgroup of approximately one third of all randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 23 Hours 45 Minutes and From 12 Hours to 23 Hours 45 Minutes Post-dose at Weeks 12 and 52</title>
          <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; 1, 2, 3, 4, 6, 8, 10, and 12 hours; 23 hours 15 minutes; and 23 hours 45 minutes post-dose. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included the same covariates as the primary Outcome Measure.</description>
          <population>Full Analysis Set (FAS), serial spirometry subgroup: A subgroup of approximately one third of all randomized patients who received at least 1 dose of study medication.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.486" spread="0.0236"/>
                    <measurement group_id="O2" value="1.380" spread="0.0298"/>
                    <measurement group_id="O3" value="1.459" spread="0.0294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=125, 62, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.445" spread="0.0261"/>
                    <measurement group_id="O2" value="1.339" spread="0.0346"/>
                    <measurement group_id="O3" value="1.379" spread="0.0338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Moderate or Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Per Year During the Study (Baseline to Week 52)</title>
        <description>The number of moderate or severe exacerbations of COPD per year during the study was calculated by dividing the total number of exacerbations during the study by the total number of years of treatment. A COPD exacerbation was considered to be moderate if treatment with systemic corticosteroids and/or antibiotic was required. A COPD exacerbation was considered to be severe if treatment for moderate severity and hospitalization was required.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Moderate or Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Per Year During the Study (Baseline to Week 52)</title>
          <description>The number of moderate or severe exacerbations of COPD per year during the study was calculated by dividing the total number of exacerbations during the study by the total number of years of treatment. A COPD exacerbation was considered to be moderate if treatment with systemic corticosteroids and/or antibiotic was required. A COPD exacerbation was considered to be severe if treatment for moderate severity and hospitalization was required.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Exacerbations per treatment year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="268"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" lower_limit="0.496" upper_limit="0.869"/>
                    <measurement group_id="O2" value="0.80" lower_limit="0.586" upper_limit="1.105"/>
                    <measurement group_id="O3" value="0.62" lower_limit="0.614" upper_limit="1.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Experienced a Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the Study (Baseline to Week 52)</title>
        <description>A COPD exacerbation was considered to be moderate if treatment with systemic corticosteroids and/or antibiotic was required. A COPD exacerbation was considered to be severe if treatment for moderate severity and hospitalization was required.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Experienced a Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the Study (Baseline to Week 52)</title>
          <description>A COPD exacerbation was considered to be moderate if treatment with systemic corticosteroids and/or antibiotic was required. A COPD exacerbation was considered to be severe if treatment for moderate severity and hospitalization was required.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="40.2"/>
                    <measurement group_id="O3" value="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Nights With “no Nighttime Awakenings” During the Study (Baseline to Week 52)</title>
        <description>A night with “no nighttime awakenings” was defined as any night where the patient did not wake up due to 1 or more of 6 symptoms (respiratory symptoms, cough, wheeze, amount of sputum, color of sputum, and breathlessness). Symptoms occurring during the previous 12 hours were recorded each morning and evening by the patient in an electronic diary. The percentage of nights with ‘no nighttime awakenings’ was calculated as the total number of nights with “no nighttime awakenings” over the 52 week treatment period divided by the total number of nights where diary recordings were made.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Nights With “no Nighttime Awakenings” During the Study (Baseline to Week 52)</title>
          <description>A night with “no nighttime awakenings” was defined as any night where the patient did not wake up due to 1 or more of 6 symptoms (respiratory symptoms, cough, wheeze, amount of sputum, color of sputum, and breathlessness). Symptoms occurring during the previous 12 hours were recorded each morning and evening by the patient in an electronic diary. The percentage of nights with ‘no nighttime awakenings’ was calculated as the total number of nights with “no nighttime awakenings” over the 52 week treatment period divided by the total number of nights where diary recordings were made.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Percentage of nights</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.36" spread="1.842"/>
                    <measurement group_id="O2" value="52.15" spread="2.239"/>
                    <measurement group_id="O3" value="55.47" spread="2.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With “no Daytime Symptoms” During the Study (Baseline to Week 52)</title>
        <description>A day with “no daytime symptoms” was defined as any day where the patient recorded no cough, no wheeze, no production of sputum, no feeling of breathlessness (other than when running), and no puffs of rescue medication during the previous 12 hours in evening entry in the electronic patient diary. The percentage of days with “no daytime symptoms” was calculated as the total number of days with “no daytime symptoms” over the 52 week treatment period divided by the total number of days where diary recordings were made.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With “no Daytime Symptoms” During the Study (Baseline to Week 52)</title>
          <description>A day with “no daytime symptoms” was defined as any day where the patient recorded no cough, no wheeze, no production of sputum, no feeling of breathlessness (other than when running), and no puffs of rescue medication during the previous 12 hours in evening entry in the electronic patient diary. The percentage of days with “no daytime symptoms” was calculated as the total number of days with “no daytime symptoms” over the 52 week treatment period divided by the total number of days where diary recordings were made.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.54" spread="1.208"/>
                    <measurement group_id="O2" value="3.81" spread="1.431"/>
                    <measurement group_id="O3" value="7.14" spread="1.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of “Days Able to Perform Usual Daily Activities” During the Study (Baseline to Week 52)</title>
        <description>A “day able to perform usual daily activities” was defined as any day where the patient recorded in their electronic diary in the evening that they were not prevented from performing their usual daily activities due to respiratory symptoms during the previous 12 hours. The percentage of “days able to perform usual daily activities” was calculated as the total number of “days able to perform usual daily activities” over the 52 week treatment period divided by the total number of days where diary recordings were made.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of “Days Able to Perform Usual Daily Activities” During the Study (Baseline to Week 52)</title>
          <description>A “day able to perform usual daily activities” was defined as any day where the patient recorded in their electronic diary in the evening that they were not prevented from performing their usual daily activities due to respiratory symptoms during the previous 12 hours. The percentage of “days able to perform usual daily activities” was calculated as the total number of “days able to perform usual daily activities” over the 52 week treatment period divided by the total number of days where diary recordings were made.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.02" spread="1.883"/>
                    <measurement group_id="O2" value="36.18" spread="2.270"/>
                    <measurement group_id="O3" value="38.09" spread="2.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Daily Total Symptom Score During the Study (Baseline to Week 52)</title>
        <description>The daily total symptom score was defined as the sum of the morning and evening patient self-reported diary assessments of 6 symptoms (respiratory symptoms/impact on daily activities, cough, wheeze, amount of sputum, color of sputum, and breathlessness). Means for baseline (14 day maximum run-in period) and the 52 week treatment period were calculated. Mean scores ranged from 0-18, with a higher score indicating worse symptoms. A negative change score indicated improvement.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrronium Bromide 50 μg</title>
            <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Glycopyrronium Bromide</title>
            <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 μg</title>
            <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Daily Total Symptom Score During the Study (Baseline to Week 52)</title>
          <description>The daily total symptom score was defined as the sum of the morning and evening patient self-reported diary assessments of 6 symptoms (respiratory symptoms/impact on daily activities, cough, wheeze, amount of sputum, color of sputum, and breathlessness). Means for baseline (14 day maximum run-in period) and the 52 week treatment period were calculated. Mean scores ranged from 0-18, with a higher score indicating worse symptoms. A negative change score indicated improvement.</description>
          <population>Full Analysis Set (FAS): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="0.125"/>
                    <measurement group_id="O2" value="-1.42" spread="0.149"/>
                    <measurement group_id="O3" value="-1.87" spread="0.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Glycopyrronium Bromide 50 μg</title>
          <description>Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="E2">
          <title>Placebo to Glycopyrronium Bromide</title>
          <description>Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
        <group group_id="E3">
          <title>Tiotropium 18 μg</title>
          <description>Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Rectal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Collapse of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Heat exhaustion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Incisional hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Splenic injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Biliary neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Lentigo maligna stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Polycythaemia vera</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Testicular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pulmonary toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="305" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="156" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

